Hemorrhagic Events during Therapy with Recombinant Tissue Plasminogen Activator, Heparin, and Aspirin for Unstable Angina (Thrombolysis in Myocardial Ischemia, Phase IIIB Trial)

American Journal of Cardiology

Volumn 79, Issue 4, 1997, Pages 391-396

  Bovill, Edwin G ^a   Tracy, Russell P ^b   Knatterud, Genell L ^b   Stone, Peter H ^b   Nasmith, Jim ^b   Gore, Joel M ^b   Thompson, Bruce W ^b   Tofler, Geoffrey H ^b   Kleiman, Neal S ^b   Cannon, Christopher ^b   Braunwald, Eugene ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HEPARIN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; ASPIRIN; HEMORRHAGE; HEPARIN; HUMANS; PLASMINOGEN ACTIVATORS; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0031568685     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00773-4     Document Type: Article

References (20)

1. TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-Wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994;89:1545-1556.
2. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. Ann Int Med 1991;115:256-265.
3. Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Thromb Haemost 1988;59:133-137.
4. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
5. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction. Mechanisms and Management. Ann Int Med 1989;111:1010-1022.
6. Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90:1624-1630.
7. GUSTO-IIA. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 1994;90: 1631-1637.
8. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-1642.
9. Simoons ML, Maggion AP, Knatterud G, Leimberger JD, Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R, Braunwald E. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342:1523-1528.
10. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemotol 1957;17:237-246.
11. Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP. Fibrin fragment D-dimer and fibrinogen Bβ peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 1990;76:1341-1348.
12. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985;54:884-687.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
14. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
15. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-200.
16. SAS Technical Report P-229: SAS/STAT Software: Changes and Enhancement. SAS Institute: Cary, North Carolina 1992;433-480.
17. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945;1:80-83.
18. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
19. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neil WW. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588.
20. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute MI. Results from the GUSTO-I trial. Circulation 1996;93:870-878.